Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salatac is an approved topical combination therapy developed by Diomed (marketed through Dermal Laboratories) for the treatment of warts, verrucas, corns, and calluses. It is formulated as an evaporative collodion-like gel containing salicylic acid (12% w/w) and lactic acid (4% w/w). Upon application, the gel forms a cohesive, adhesive film on the skin. Salicylic acid acts as a keratolytic agent, inducing the slow destruction of the thickened stratum corneum by reducing corneocyte adhesion and causing the epithelium to swell and desquamate. Lactic acid serves to enhance the availability of salicylic acid from the dried film and provides additional antiseptic and caustic properties. The product is indicated for use in adults, children, and the elderly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Salatac.